lutetium [177Lu] vipivotide tetraxetan + androgen receptor pathway inhibitor

This is a **combination therapy** consisting of **lutetium [177Lu] vipivotide tetraxetan** (a targeted radioligand therapeutic, also known as PLUVICTO or formerly ^177Lu-PSMA-617) and an **androgen receptor pathway inhibitor** (typically a small molecule such as enzalutamide or abiraterone, though the specific AR pathway inhibitor can vary depending on protocol or trial). Lutetium [177Lu] vipivotide tetraxetan is a radiolabeled compound targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells, delivering beta radiation locally to tumor sites. Androgen receptor pathway inhibitors inhibit androgen receptor signaling, essential for prostate cancer progression, and are standard of care in prostate cancer therapy. This combination is studied in **metastatic castration-resistant prostate cancer (mCRPC)**, including patients previously treated with AR pathway inhibition and taxane-based chemotherapy[1][3]. The combination aims to improve efficacy through dual targeting: radioligand therapy plus further suppression of androgen signaling. The combination can also refer to ongoing trials in related populations (e.g., mHSPC), with AR pathway inhibitor choice defined by study protocol.

Brand names

Pluvicto (for lutetium (177Lu) vipivotide tetraxetan)no combination brand name known

Other names

^177Lu-PSMA-617 + androgen receptor pathway inhibitor